Castle Biosciences, Inc. Common Stock

Day range

$32.97 – $33.79

Open

$33.20

Prev close

$33.08

Volume

90.1K

Market cap

$1.01B

Shares out

30.55M

P/E

—

P/S

2.83

P/B

2.15

P/FCF

—

ROE

-4.1%

ROA

-3.5%

Debt/Equity

0.02

Div yield

0.00%

As of Oct 23, 2026

• Annual meeting resultsMay 29, 2026

  On May 28, 2026, Castle Biosciences, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on the following matters and cast their votes as set forth below: Proposal 1. Election of Directors... Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm... Proposal 3. Approval of the Compensation of the Company's Named Executive Officers... Proposal 4. Approval of the Company's Non-Employee Director Compensation Policy.

• Investor presentationMay 6, 2026

  On May 6, 2026, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.

• Preliminary resultsJan 13, 2026

  On January 11, 2026, Castle Biosciences, Inc. (the "Company") issued a press release announcing certain preliminary performance results for the fourth quarter of 2025 and for the year ended December 31, 2025.

• Investor presentationNov 3, 2025

  On November 3, 2025, the Company made available the slide presentation attached hereto as Exhibit 99.2. Information from this slide presentation may also be used by the management of the Company in future meetings regarding the Company.

• Bylaw amendmentAug 8, 2025

  On August 5, 2025, the board of directors (the "Board") of Castle Biosciences, Inc. (the "Company") adopted amended and restated bylaws of the Company (as amended and restated, the "A&R Bylaws"), effective as of such adoption date. The following is a summary of the material changes made to the Company's amended and restated bylaws...

Days to cover

4.8

Short interest

2M

Avg volume

419.63K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Winner of My Stock-Picking Derby Sold Her Top Pick Too Soon
  positiveInvesting.com· May 14, 2026
• DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk
  positiveGlobeNewswire Inc.· Mar 9, 2026
• Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis
  positiveGlobeNewswire Inc.· Feb 19, 2026
• Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer
  positiveGlobeNewswire Inc.· Dec 12, 2025
• Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year
  positiveGlobeNewswire Inc.· Nov 17, 2025